Lifesci Capital Brokers Decrease Earnings Estimates for PVLA

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Investment analysts at Lifesci Capital lowered their FY2026 earnings per share (EPS) estimates for Palvella Therapeutics in a note issued to investors on Wednesday, April 1st. Lifesci Capital analyst S. Slutsky now expects that the company will post earnings per share of ($6.11) for the year, down from their prior estimate of ($4.49). The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by ($0.13).

Several other analysts have also recently weighed in on the stock. Stifel Nicolaus set a $250.00 price objective on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. BTIG Research raised their target price on Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Canaccord Genuity Group lifted their target price on Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Raymond James Financial reiterated a “strong-buy” rating and issued a $193.00 price target on shares of Palvella Therapeutics in a research report on Tuesday, December 16th. Finally, UBS Group reissued a “buy” rating and issued a $143.00 price target on shares of Palvella Therapeutics in a research note on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $198.07.

Palvella Therapeutics Price Performance

PVLA opened at $123.46 on Friday. Palvella Therapeutics has a fifty-two week low of $18.23 and a fifty-two week high of $151.18. The company’s 50 day moving average price is $106.43 and its two-hundred day moving average price is $92.07. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -33.28 and a beta of -0.20.

Institutional Investors Weigh In On Palvella Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Archer Investment Corp acquired a new position in Palvella Therapeutics in the third quarter valued at approximately $28,000. Group One Trading LLC grew its position in shares of Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after buying an additional 200 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of Palvella Therapeutics in the 3rd quarter valued at $36,000. JPMorgan Chase & Co. increased its stake in shares of Palvella Therapeutics by 108,066.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after acquiring an additional 3,242 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Palvella Therapeutics during the 2nd quarter valued at $85,000. 40.11% of the stock is currently owned by institutional investors.

Insider Activity at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total value of $507,592.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director George M. Jenkins acquired 4,000 shares of the company’s stock in a transaction dated Friday, February 27th. The stock was acquired at an average cost of $125.00 per share, for a total transaction of $500,000.00. Following the completion of the purchase, the director directly owned 187,171 shares in the company, valued at $23,396,375. This trade represents a 2.18% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 20.50% of the stock is owned by company insiders.

More Palvella Therapeutics News

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: HC Wainwright raised long‑term EPS forecasts sharply (FY2028 → $2.08, FY2029 → $9.00, FY2030 → $22.29) and reiterated a “Buy” rating with a $270 price target — a bullish signal that implies substantial upside if clinical/financial execution meets those long‑range assumptions. HC Wainwright long-term upgrades
• Positive Sentiment: Coverage note / media mention (Chardan Capital cited by American Banking News) flagged upside potential and said PVLA stock price is expected to rise — additional third‑party bullish commentary that can amplify investor interest. Palvella Therapeutics Stock Price Expected to Rise
• Neutral Sentiment: HC Wainwright published quarterly 2026 EPS schedules (Q1: -$0.89, Q2: -$1.02, Q3: -$1.19, Q4: -$1.30) — useful near‑term reference points for modeling cash burn and runway but confirm continued losses through 2026. Qtr estimates
• Negative Sentiment: HC Wainwright cut near‑term FY2026 and FY2027 EPS estimates (FY2026 revised to -$4.41; FY2027 to -$3.76), signaling a weaker short‑term profit trajectory than previously expected — a headwind for investors focused on nearer‑term fundamentals. Near-term cuts
• Negative Sentiment: Lifesci Capital also lowered FY2026 EPS (to -$6.11), adding another analyst voice forecasting larger near‑term losses, which could increase concern about dilution, additional financing needs, or slower commercialization. Lifesci Capital revision
• Negative Sentiment: Recent reported quarterly results missed EPS expectations (last EPS -$1.08 vs. consensus -$0.95), a reminder of execution risk and a factor that likely makes some investors cautious despite bullish long‑term forecasts.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.